Introduction

This publication has 9 references indexed in Scilit:

• Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
  Journal of Clinical Oncology, 1999
• The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy
  The International Journal of Cell Cloning, 1998
• Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
  Journal of Clinical Oncology, 1998
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
  Journal of Clinical Oncology, 1996
• Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
  Breast Cancer Research and Treatment, 1992
• Humanization of an anti-p185HER2 antibody for human cancer therapy.
  Proceedings of the National Academy of Sciences, 1992
• Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
  Science, 1989
• p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.
  Molecular and Cellular Biology, 1989
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987